Milestone Pharmaceuticals Inc. (MIST)

NASDAQ: MIST · IEX Real-Time Price · USD
0.00 (0.00%)
At close: Jul 5, 2022 12:00 AM
+0.30 (4.94%)
Pre-market: Jul 6, 2022 8:45 AM EDT

Company Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.

The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans.

The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Logo
Country United States
Founded 2003
Industry Pharmaceuticals
Sector Health Care
Employees 29

Contact Details

1111 Dr. Frederik-Philips Boulevard
Montreal, QC H4M 2X6
Phone 514 336 0444

Stock Details

Ticker Symbol MIST
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 1408443
CUSIP Number 59935V107
ISIN Number CA59935V1076
SIC Code 2834

Key Executives

Name Position
Joseph G. Oliveto M.B.A. Chief Executive Officer, President and Director
Amit Hasija Chief Financial Officer and Executive Vice President of Corporate Development
Dr. Francis Plat FAHA, M.D. Chief Scientific Officer
Dr. Philippe Douville Founder, Strategic Advisor and Member of Scientific Advisory Board
Jeff Nelson Chief Operating Officer
Kimberly Sheehan Vice President of Human Resources
Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. Chief Medical Advisor and Member of the Scientific Advisory Board
Dr. Guy Rousseau SVice President of Regulatory Affairs and Quality Management
Lorenz Muller Chief Commercial Officer
Dr. David B. Bharucha FACC, M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Jun 1, 2022 4 Statement of changes in beneficial ownership of securities
May 12, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 2, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 2, 2022 DEF 14A Other definitive proxy statements
Apr 21, 2022 PRE 14A Other preliminary proxy statements
Mar 24, 2022 8-K Current report
Mar 24, 2022 S-8 Securities to be offered to employees in employee benefit plans
Mar 24, 2022 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 23, 2022 4 Statement of changes in beneficial ownership of securities
Mar 23, 2022 4 Statement of changes in beneficial ownership of securities